Insmed stock hits 52-week high at 106.84 USD
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Insmed Inc (1INSM)
Insmed Inc stock price live, this page displays NASDAQ INSM stock exchange data. View the INSM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Insmed Inc real time stock price chart below.
What Is the Insmed Inc Stock Price Today?
The Insmed Inc stock price today is 94.50.
What Is the Stock Symbol for Insmed Inc?
The stock symbol for Insmed Inc is ""INSM.""
What Stock Exchange Does Insmed Inc Trade On?
Insmed Inc is listed and trades on the NASDAQ stock exchange.
Is Insmed Inc a Good Stock to Buy?
Determining whether Insmed Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INSM quote. (ISIN: US4576693075)
What Is the Insmed Inc Stock Price Today?
The Insmed Inc stock price today is 94.50.
What Is the Stock Symbol for Insmed Inc?
The stock symbol for Insmed Inc is ""INSM.""
What Stock Exchange Does Insmed Inc Trade On?
Insmed Inc is listed and trades on the NASDAQ stock exchange.
Is Insmed Inc a Good Stock to Buy?
Determining whether Insmed Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INSM quote. (ISIN: US4576693075)
94.50
+2.00(+2.16%)
Closed·
Fair Value
An estimate of a Insmed Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
94.50
94.50
52 wk Range
62.50
94.50
1INSM Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
Trading near 52-week High
More Info
Fair Value
An estimate of a Insmed Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
94.5094.50
52 wk Range
62.5094.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
1INSM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Insmed Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
- Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Insmed stock hits 52-week high at 106.84 USD
- Investing.com
- Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Insmed receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Insmed chair and CEO Lewis sells $699k in shares
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Insmed Inc Company Profile
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Compare 1INSM to Peers and Sector
Metrics to compare | 1INSM | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship Relationship1INSMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −20.2x | −3.8x | −0.5x | |
PEG Ratio | 1.53 | −0.11 | 0.00 | |
Price/Book | 205.9x | 3.5x | 2.6x | |
Price / LTM Sales | 53.6x | 45.4x | 3.3x | |
Upside (Analyst Target) | - | 163.9% | 42.4% | |
Fair Value Upside | Unlock | 20.1% | 7.2% | Unlock |
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-1.42 / --
Revenue / Forecast
92.82M / --
People Also Watch
FAQ
What Stock Exchange Does Insmed Inc Trade On?
Insmed Inc is listed and trades on the Milan Stock Exchange stock exchange.
What Is the Stock Symbol for Insmed Inc?
The stock symbol for Insmed Inc is "1INSM."
What Is the Insmed Inc Market Cap?
As of today, Insmed Inc market cap is 17.80B.
What Is Insmed Inc's Earnings Per Share (TTM)?
The Insmed Inc EPS (TTM) is -5.89.
From a Technical Analysis Perspective, Is 1INSM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Insmed Inc Stock Split?
Insmed Inc has split 0 times.
How Many Employees Does Insmed Inc Have?
Insmed Inc has 1271 employees.
What is the current trading status of Insmed Inc (1INSM)?
As of 31 Jul 2025, Insmed Inc (1INSM) is trading at a price of 94.50, with a previous close of 92.50. The stock has fluctuated within a day range of 94.50 to 94.50, while its 52-week range spans from 62.50 to 94.50.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.